LION: Lifting Immune CheckpOints with NSAIDs

  • Research type

    Research Study

  • Full title

    Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade

  • IRAS ID

    1004222

  • Contact name

    Anne Armstrong

  • Contact email

    anne.armstrong3@nhs.net

  • Sponsor organisation

    The Christie NHS Foundation Trust

  • Eudract number

    2021-005109-29

  • ISRCTN Number

    ISRCTN73037722

  • Research summary

    Phase II, open label, multicentre trial of the addition of celecoxib to standard of care immune-checkpoint blockade in Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC)(clear cell and papillary histological subtypes).
    This study will compare a potential new treatment combination for patients who TNBC, NSCLC and RCC. The study will check how safe, tolerable and celecoxib is in combination with standard immunotherapy +/- chemotherapy which are the first-line treatments for these patients. It is hoped the new treatments will more effective, but it’s not known at present which is why the study is being performed.

    The trial will include 89 subjects, across the three disease groups, treated at sites with oncology expertise. To participate, patients must be >18 years and have triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) or renal cell carcinoma (RCC).

    Patients will receive the following treatments dependent on their disease type:
    1. TNBC; celecoxib, atezolizumab + nab-paclitaxel
    2. NSCLC; celecoxib + pembrolizumab
    3. RCC; celecoxib, nivolumab + ipilimumab

  • REC name

    London - Fulham Research Ethics Committee

  • REC reference

    22/LO/0219

  • Date of REC Opinion

    24 May 2022

  • REC opinion

    Further Information Favourable Opinion